Nature communications · 2026
Airway immune profiles and therapeutic implications of IGF1 in eosinophilic granulomatosis with polyangiitis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dong Cong, Lu Bingtai, Zhong Changhao, Ou Changxing, Yang Xiaojing, Wang Lingwei, Zuo Xiaoyu, Xue Lingna, Lu Chenyang, Wang Shang, Wen Junjie, Ma Jianjuan, Deng Zhenan, Liu Yiyi, Ma Liuheyi, Liu Ming, Lew Andrew M, Mukherjee Manali, Nair Parameswaran, Zhong Nanshan, Chen Rongchang, Chen Zhanghua, Zhang Yuxia, Zhang Qingling
Аннотация
Eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma (SEA) share a Type 2 (T2) inflammatory signature but exhibit distinct pathophysiology. We hypothesized that EGPA involves additional inflammatory mechanisms, beyond T2 immunity, that drive its systemic manifestations and treatment resistance. Using single-cell RNA sequencing, we identify interferon (IFN-I)-driven inflammation in EGPA, in contrast to TNF predominant pathway activation in SEA. IL1B+MX1+ neutrophils in EGPA express IFN-stimulated genes and promote tertiary lymphoid structure formation with autoantibody production. In addition, other IFN-activated granulocytes, including APOC1+ eosinophils, SCN7A+ mast cells, and basophils, further contribute to immune dysregulation in EGPA, unlike TNF activated granulocytes in SEA. Longitudinal single-cell analysis of EGPA reveals an IGF1+ macrophage population linked to EGPA relapse. In animal models of both conditions, IGF1 blockade attenuates T2 inflammation, mucin production, and goblet cell hyperplasia, highlighting IGF1 as a possible therapeutic target in T2 inflammation disease.